Huang Qionglian, Wang Jue, Ning Hanjuan, Liu Weiwei, Han Xianghui
Institute of Chinese Traditional Surgery, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Breast Cancer. 2025 Jan;32(1):43-59. doi: 10.1007/s12282-024-01635-w. Epub 2024 Sep 30.
The therapy for breast cancer (BC), to date, still needs improvement. Apart from traditional therapy methods, biological therapy being explored opens up a novel avenue for BC patients. Integrin β1 (ITGβ1), one of the largest subgroups in integrin family, is a key player in cancer evolution and therapy. Recent researches progress in the relationship of ITGβ1 level and BC, finding that ITGβ1 expression evidently concerns BC progression. In this chapter, we outline diverse ITGβ1-based mechanisms regarding to the promoted effect of ITGβ1 on BC cell structure rearrangement and malignant phenotype behaviors, the unfavorable patient prognosis conferred by ITGβ1, BC therapy tolerance induced by ITGβ1, and lastly novel inhibitors targeting ITGβ1 for BC therapy. As an effective biomarker, ITGβ1 undoubtedly emerges one of targeted-therapy opportunities of BC patients in future. It is a necessity focusing on scientific and large-scale clinical trials on the validation of targeted-ITGβ1 drugs for BC patients.
迄今为止，乳腺癌（BC）的治疗仍有待改进。除了传统治疗方法外，正在探索的生物治疗为BC患者开辟了一条新途径。整合素β1（ITGβ1）是整合素家族中最大的亚群之一，是癌症进展和治疗的关键因素。最近关于ITGβ1水平与BC关系的研究进展发现，ITGβ1表达明显与BC进展有关。在本章中，我们概述了基于ITGβ1的多种机制，包括ITGβ1对BC细胞结构重排和恶性表型行为的促进作用、ITGβ1导致的患者预后不良、ITGβ1诱导的BC治疗耐受性，以及最后针对ITGβ1用于BC治疗的新型抑制剂。作为一种有效的生物标志物，ITGβ1无疑成为未来BC患者靶向治疗的机会之一。有必要针对BC患者开展关于验证靶向ITGβ1药物的科学且大规模的临床试验。
